MANOEL NERES SANTOS JUNIOR

Dr. MANOEL NERES SANTOS JUNIOR

Federal University of Bahia, Salvador, Bahia, Brazil
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
KRKelly Almeida Andrade Ferreira Rebouças
Kelly Almeida Andrade Ferreira Rebouças
FNFlávio Marinho Narici
Flávio Marinho Narici
MJMANOEL NERES SANTOS JUNIOR
MANOEL NERES SANTOS JUNIOR
NNNayara Silva de Macêdo Neres
Nayara Silva de Macêdo Neres
MOMárcio Vasconcelos Oliveira
Márcio Vasconcelos Oliveira
CSCláudio Lima Souza
Cláudio Lima Souza
The serological screening of blood donors has been instituted by the Brazilian Ministry of Health and is mandatory in the research on several diseases transmissible through blood transfusion. Blood banks need to establish a screening service capable of reducing associated transfusions risks. The objective of this study was to establish the prevalence of transfusion-transmissible infection markers in donors at a hemotherapy service located in southwest Bahia, Brazil. A retrospective study was performed between 2010 and 2016. Variables, such as the characterization of donors who were suitable and unsuitable for donation (in clinical screening), stratification by gender and age group and unsuitable samples for reactive test results (in serological screening) by aspecific antibodies against hepatitis B virus (anti-HBc and HBsAg), hepatitis C virus (anti-HCV), human T-lymphotropic virus (anti-HTLV I/II), HIV virus (anti-HIV I/II), chagas disease, and syphilis markers, were evaluated. Collected data showed that 3.13% of the donors were considered unsuitable for serological screening and that the prevalence of reactive test results was higher in donors aged between 30 and 39 years and in males. The means of the serological markers was 1.09% for syphilis reagents, 0.63% for anti-HIV I/II, 0.51% for anti-HBc and anti-HCV, 0.15% for HBsAg, 0.14% for HTLV I/II and 0.10% for Chagas disease. These results reflect the importance of awareness campaigns on sexually transmitted diseases and transfusion safety measures taken by hemotherapy services.

16 May 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
MJMANOEL NERES SANTOS JUNIOR
MANOEL NERES SANTOS JUNIOR
WNWanderson Souza Neves
Wanderson Souza Neves
RSRonaldo Santos
Ronaldo Santos
Palloma Porto AlmeidaPalloma Porto Almeida
Palloma Porto Almeida
JFJanaina Marinho Fernandes
Janaina Marinho Fernandes
LMLucas Miranda Marques
Lucas Miranda Marques
Ureaplasma diversum is a bacterial pathogen that infects cattle and can cause severe inflammation of the genital and reproductive systems. Lipid-associated membrane proteins (LAMPs), including GUDIV-103, are the main virulence factors in this bacterium. In this study, we heterologously expressed recombinant GUDIV-103 (rGUDIV-103) in Escherichia coli, purified it, and evaluated its immunological reactivity and immunomodulatory effects in bovine peripheral blood mononuclear cells (PBMCs). Samples from rabbits inoculated with purified rGUDIV-103 were analysed using indirect enzyme-linked immunosorbent assay and dot blotting to confirm polyclonal antibody production and assess kinetics, respectively. The expression of this lipoprotein in field isolates was confirmed via Western blotting with anti-rGUDIV-103 serum and hydrophobic or hydrophilic proteins from 42 U. diversum strains. Moreover, the antibodies produced against the U. diversum ATCC 49783 strain recognised rGUDIV-103. The mitogenic potential of rGUDIV-103 was evaluated using a lymphoproliferation assay in 5(6)-carboxyfluorescein diacetate succinimidyl ester–labelled bovine PBMCs, where it induced lymphocyte proliferation. Quantitative polymerase chain reaction analysis revealed that the expression of interleukin-1β, toll-like receptor (TLR)-α, TLR2, TLR4, inducible nitric oxide synthase, and caspase-3–encoding genes increased more in rGUDIV-103–treated PBMCs than in untreated cells (p < 0.05). Treating PBMCs with rGUDIV-103 increased nitric oxide and hydrogen peroxide levels. The antigenic and immunogenic properties of rGUDIV-103 suggested its suitability for immunobiological application.

11 July 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
Beatriz Almeida SampaioBeatriz Almeida Sampaio
Beatriz Almeida Sampaio
MBMaysa Santos Barbosa
Maysa Santos Barbosa
MOMatheus Gonçalves de Oliveira
Matheus Gonçalves de Oliveira
MJMANOEL NERES SANTOS JUNIOR
MANOEL NERES SANTOS JUNIOR
BGBruna Carolina de Brito Guimarães
Bruna Carolina de Brito Guimarães
LMLucas Miranda Marques
Lucas Miranda Marques
Background/Objectives: Contagious agalactia (CA) is a disease typically caused by Mycoplasma agalactiae, affecting small ruminants worldwide and being endemic in certain countries. CA causes severe economic losses due to mastitis, agalactia, and arthritis. As an alternative to existing immunoprophylactic measures, this study aimed to develop a recombinant subunit vaccine against M. agalactiae and evaluate its specific immune response in goats. Methods: Goats were divided into three groups: group 1 received recombinant proteins (P40 and MAG_1560), group 2 received formalin-inactivated M. agalactiae, and group 3 received Tris-buffered saline (negative control). All solutions were emulsified in Freund’s adjuvant. Animals were monitored for 181 days. IgG antibody production was assessed by ELISA, and peripheral blood mononuclear cells (PBMCs) were analyzed by real-time PCR for the expression of IL-1β, IFN-γ, IL-12, and MHC class II genes. Results: M. agalactiae-specific antibody response was observed for six months in the sera of animals from group 1. Analysis of cytokine gene expression revealed increased IL-1β mRNA levels over time in both experimental groups. In group 1, IFN-γ mRNA levels increased with P40 stimulation and decreased with MAG_1560. IL-12 mRNA expression decreased over time in group 1 with P40 stimulation, whereas group 2 showed increased IL-12 expression for both proteins. MHC-II expression was stimulated in both groups. Conclusions: The recombinant proteins induced antibody production and cytokine expression, demonstrating immunogenic potential and supporting their promise as vaccine candidates capable of eliciting both humoral and cellular immune responses against M. agalactiae.

21 July 2022 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
LSLucas Santana Coelho da Silva
Lucas Santana Coelho da Silva
Caroline Tianeze de CastroCaroline Tianeze de Castro
Caroline Tianeze de Castro
CGCamila Pachêco Gomes
Camila Pachêco Gomes
MJMANOEL NERES SANTOS JUNIOR
MANOEL NERES SANTOS JUNIOR
Maysa Santos BarbosaMaysa Santos Barbosa
Maysa Santos Barbosa
LMLucas Miranda Marques
Lucas Miranda Marques
The present systematic review and meta-analysis aimed to investigate the use of recombinant proteins to diagnose STIs and evaluate the performance of the tests identified. The databases, SciELO, PubMed, CAPES Journal Portal, and LILACS, were searched according to the PRISMA protocol. A study was considered eligible if it met previously defined criteria. The risk of study bias was assessed according to the QUADAS-2 protocol. The meta-analysis was performed based on the random-effects model, and heterogeneity was quantified using the I² statistic. A total of 1,355 studies were selected, 30 of which were relevant to the following: human immunodeficiency virus (12/30), Treponema pallidum (10/30), Chlamydia trachomatis (3/30), herpes simplex virus (HSV, 2/30), Trichomonas vaginalis (2/30), and HSV/cytomegalovirus (1/30). The main serological tests were ELISA and immunochromatography. The risk of bias was low for most included studies. According to each microorganism, the meta-analysis revealed satisfactory sensitivity and specificity for the analyzed tests. The findings reinforce the relevance of diagnostic tests based on recombinant proteins as viable alternatives for production and inclusion in clinical practice. PROSPERO registration number: CRD42020206331.